RU2604062C2 - ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 - Google Patents

ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 Download PDF

Info

Publication number
RU2604062C2
RU2604062C2 RU2013103539/04A RU2013103539A RU2604062C2 RU 2604062 C2 RU2604062 C2 RU 2604062C2 RU 2013103539/04 A RU2013103539/04 A RU 2013103539/04A RU 2013103539 A RU2013103539 A RU 2013103539A RU 2604062 C2 RU2604062 C2 RU 2604062C2
Authority
RU
Russia
Prior art keywords
hydroxy
phenyl
chloro
amide
amino
Prior art date
Application number
RU2013103539/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013103539A (ru
Inventor
Нидхи АРОРА
Шаоцин ЧЭНЬ
Йоханнес Корнелиус ГЕРМАНН
Андреас КУГЛЬСТАТТЕР
Шарада Шенви ЛАБАДИ
Клара Йеу Йен ЛИН
Мэтью К. ЛУКАС
Эми Джеральдин МОР
Ева ПАПП
Франсиско Ксавьер ТАЛАМАС
Ютта ВАННЕР
Цзаньшэн ЧЖАЙ
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2013103539A publication Critical patent/RU2013103539A/ru
Application granted granted Critical
Publication of RU2604062C2 publication Critical patent/RU2604062C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2013103539/04A 2010-07-13 2011-07-08 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 RU2604062C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36385510P 2010-07-13 2010-07-13
US61/363,855 2010-07-13
US201161485145P 2011-05-12 2011-05-12
US61/485,145 2011-05-12
PCT/EP2011/061598 WO2012007375A1 (en) 2010-07-13 2011-07-08 Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators

Publications (2)

Publication Number Publication Date
RU2013103539A RU2013103539A (ru) 2014-08-20
RU2604062C2 true RU2604062C2 (ru) 2016-12-10

Family

ID=45467432

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013103539/04A RU2604062C2 (ru) 2010-07-13 2011-07-08 ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4

Country Status (11)

Country Link
US (4) US20120015962A1 (enExample)
EP (2) EP3252054A1 (enExample)
JP (3) JP5985473B2 (enExample)
KR (2) KR20190077610A (enExample)
CN (3) CN110003219A (enExample)
AR (1) AR082154A1 (enExample)
BR (1) BR112013000868A2 (enExample)
CA (1) CA2802641C (enExample)
MX (2) MX358682B (enExample)
RU (1) RU2604062C2 (enExample)
WO (1) WO2012007375A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072599B2 (en) 2017-02-01 2021-07-27 Biotheryx, Inc. Pyrazole compounds and uses thereof
RU2770835C1 (ru) * 2018-08-27 2022-04-22 Шэньчжэнь Бо Ли Цзянь Медисин Ко., Лтд. Соединения пиразола, их фармацевтические композиции и их применение
RU2846204C2 (ru) * 2018-11-30 2025-09-01 Кимера Терапьютикс, Инк. Агенты, разлагающие irak, и их применения

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
CA2802641C (en) 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
JP5797345B2 (ja) * 2011-12-30 2015-10-21 ハンミ ファーム. シーオー., エルティーディー. プロテインキナーゼに対する阻害活性を有するチエノ[3,2−d]ピリミジン誘導体
RU2637925C2 (ru) * 2012-01-10 2017-12-08 Ф. Хоффманн-Ля Рош Аг Соединения тиенопиримидина
WO2013106535A1 (en) 2012-01-10 2013-07-18 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014003483A1 (en) * 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
CA2878621C (en) 2012-07-10 2020-09-15 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
US20140018361A1 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2015528801A (ja) 2012-07-11 2015-10-01 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
HK1216859A1 (zh) 2013-01-10 2016-12-09 Nimbus Iris, Inc. Irak抑制劑和其用途
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
HUE050215T2 (hu) 2013-01-15 2020-11-30 Incyte Holdings Corp Pim kináz inhibitorokként hasznos tiazolkarboxamid és piridinkarboxamid vegyületek
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP2016512239A (ja) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な化合物
EP2970288A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3019171B1 (en) * 2013-07-11 2018-09-05 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
TW201605866A (zh) * 2013-08-23 2016-02-16 英塞特公司 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物
CA2925211A1 (en) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
PL3077397T3 (pl) 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
US9732095B2 (en) 2014-01-13 2017-08-15 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US9346815B2 (en) * 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
SG10201902206QA (en) 2014-06-05 2019-04-29 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
EP3715346B1 (en) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
KR102662215B1 (ko) 2014-11-06 2024-05-02 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
PT3221306T (pt) * 2014-11-20 2020-02-19 Merck Patent Gmbh Compostos de heteroarilo como inibidores de irak e utilização dos mesmos
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
US10329295B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of IRAK4 activity
EP3268003B1 (en) * 2015-03-12 2020-07-29 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
EP3268004B1 (en) * 2015-03-12 2019-12-18 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3322698A4 (en) * 2015-07-15 2019-01-09 Aurigene Discovery Technologies Limited INDAZOL AND AZAINDAZONE COMPOUNDS AS IRAQ-4 INHIBITORS
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
MX382996B (es) * 2015-09-17 2025-03-13 Hope City Inhibidores de pcna
CN105237414B (zh) * 2015-09-30 2017-03-22 浙江永宁药业股份有限公司 ivacaftor中间体及其制备方法和用途
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3394066A2 (en) * 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
JP7034935B2 (ja) 2016-04-06 2022-03-14 リソソーマル・セラピューティクス・インコーポレイテッド ピロロ[1,2-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
WO2017192841A1 (en) * 2016-05-04 2017-11-09 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
CN106222183B (zh) * 2016-07-25 2019-11-08 南通大学 靶向人irak1基因的小干扰rna及其应用
WO2018083085A1 (en) 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
CN110691589A (zh) 2017-03-31 2020-01-14 奥列基因发现技术有限公司 用于治疗血液病的化合物和组合物
CN106946890A (zh) * 2017-04-26 2017-07-14 中国药科大学 吡啶类irak4抑制剂、其制备方法及应用
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
EP3642199B1 (en) * 2017-06-21 2022-04-27 F. Hoffmann-La Roche AG Benzofurans as irak4 modulators
CN111094292A (zh) * 2017-06-21 2020-05-01 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
JP2020524663A (ja) * 2017-06-21 2020-08-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Irak4調節因子としてのイソインドリノン誘導体
WO2019001460A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 作为 irak4 抑制剂的稠环化合物
JP7114394B2 (ja) * 2017-08-18 2022-08-08 住友化学株式会社 化合物、レジスト組成物及びレジストパターンの製造方法
EP3684365A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND USES OF SUCH
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
FI3704108T3 (fi) 2017-10-31 2024-05-23 Curis Inc Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
EP3717492B1 (en) 2017-11-30 2023-05-24 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CN112236429B (zh) * 2018-04-05 2024-10-11 默克专利有限公司 用作ii型irak抑制剂的杂芳基化合物及其用途
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
TWI898556B (zh) 2018-07-13 2025-09-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
SG11202104229WA (en) 2018-10-30 2021-05-28 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020263980A1 (en) * 2019-06-27 2020-12-30 Biogen Ma Inc. Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease
AU2020360000B2 (en) 2019-10-02 2023-04-20 Kainos Medicine, Inc. N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
IL297050A (en) 2020-04-04 2022-12-01 Pfizer Methods of treating the 2019 corona virus disease
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4223750B1 (en) * 2020-09-30 2025-06-25 Asahi Kasei Pharma Corporation Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
IL307465A (en) 2021-04-08 2023-12-01 Curis Inc Combined therapies for cancer treatment
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
KR102869914B1 (ko) * 2021-10-28 2025-10-13 재단법인 대구경북첨단의료산업진흥재단 신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
CN118302168A (zh) 2021-10-29 2024-07-05 凯麦拉医疗公司 Irak4降解剂和其制备
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012103487A (ru) * 2009-07-02 2013-08-10 Дженентек, Инк. Ингибирующие jak соединения на основе пиразолопиримидина и способы

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436628B1 (en) * 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
WO2003030902A1 (en) 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7393873B2 (en) * 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
EP1731494A4 (en) 2004-03-31 2008-03-26 Kuraray Co METHOD FOR PRODUCING A HALOGENATED UNSATURATED CARBONYL COMPOUND
JP2008013527A (ja) 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体
US20080176870A1 (en) * 2006-11-20 2008-07-24 Bert Nolte Heterobicyclic metalloprotease inhibitors
DK2212297T3 (da) * 2007-10-12 2011-09-05 Ingenium Pharmaceuticals Gmbh Inhibitorer af proteinkinaser
ES2710701T3 (es) * 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
JP5769199B2 (ja) * 2008-10-31 2015-08-26 ジェネンテック, インコーポレイテッド ピラゾロピリミジンjak阻害剤化合物と方法
IT1392824B1 (it) * 2009-02-13 2012-03-23 Sacmi Apparato per formare oggetti
CN101537007A (zh) * 2009-03-18 2009-09-23 中国医学科学院血液病医院(血液学研究所) N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
JP2013503188A (ja) * 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Raf阻害化合物およびその使用方法
SG182361A1 (en) 2010-01-29 2012-08-30 Hanmi Science Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
CA2802641C (en) 2010-07-13 2019-03-12 Nidhi Arora Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012103487A (ru) * 2009-07-02 2013-08-10 Дженентек, Инк. Ингибирующие jak соединения на основе пиразолопиримидина и способы

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAMADA MOHAMED IBRAHIM ET AL, Utility of cyanoacetamides as precursors to pyrazolo[3,4-d]pyrimidin-4-ones, 2-aryl-6-substituted 1,2.3-triazolo[4,5-d]pyrimidines and pyrazolo[1,2-a]pyrimidine-3-carboxamides, Heterocycles, vol. 71, N9, 2007, pp. 1951-1966. *
LIXIN QIAO ET AL, Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.19, N21, 2009, pp.6122-6126. WO 2009|047359 A1, 16.04.2009. *
WO 2010/034738 A2. *
приоритет 02.07.2009. GEORGE M. BUCKLEY ET AL, IPAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines, Bioorganic & Medicinal Chemistry Letters, vol. 18, N 12, pp.36-3660. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072599B2 (en) 2017-02-01 2021-07-27 Biotheryx, Inc. Pyrazole compounds and uses thereof
RU2761457C2 (ru) * 2017-02-01 2021-12-08 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Лтд. N1-(4-(5-(циклопропилметил)-1-метил-1h-пиразол-4-ил)пиридин-2-ил)циклогексан-1,4-диаминовые производные и родственные соединения в качестве ингибиторов сk1 и/или irak1 для лечения рака
US11999721B2 (en) 2017-02-01 2024-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pyrazole compounds and uses thereof
RU2770835C1 (ru) * 2018-08-27 2022-04-22 Шэньчжэнь Бо Ли Цзянь Медисин Ко., Лтд. Соединения пиразола, их фармацевтические композиции и их применение
US11958831B2 (en) 2018-08-27 2024-04-16 Artivila (Shenzhen) Innovation Center, Ltd. Pyrazole compounds, pharmaceutical compositions thereof and use thereof
RU2846204C2 (ru) * 2018-11-30 2025-09-01 Кимера Терапьютикс, Инк. Агенты, разлагающие irak, и их применения
US12497402B2 (en) 2023-09-01 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof

Also Published As

Publication number Publication date
US20160207936A1 (en) 2016-07-21
US9255110B2 (en) 2016-02-09
CN110003219A (zh) 2019-07-12
CN102985426B (zh) 2015-10-07
RU2013103539A (ru) 2014-08-20
AR082154A1 (es) 2012-11-14
EP2593457A1 (en) 2013-05-22
EP2593457B1 (en) 2017-08-23
EP3252054A1 (en) 2017-12-06
US20140303149A1 (en) 2014-10-09
WO2012007375A1 (en) 2012-01-19
US10023589B2 (en) 2018-07-17
KR101995013B1 (ko) 2019-07-02
CA2802641A1 (en) 2012-01-19
US20180298026A1 (en) 2018-10-18
CA2802641C (en) 2019-03-12
JP5985473B2 (ja) 2016-09-06
US20120015962A1 (en) 2012-01-19
KR20190077610A (ko) 2019-07-03
JP2018199703A (ja) 2018-12-20
MX2013000390A (es) 2013-03-08
BR112013000868A2 (pt) 2016-05-17
KR20130132396A (ko) 2013-12-04
JP6396376B2 (ja) 2018-09-26
JP2016222707A (ja) 2016-12-28
MX358682B (es) 2018-08-31
JP2013531018A (ja) 2013-08-01
CN105367577A (zh) 2016-03-02
MX340490B (es) 2016-07-11
CN102985426A (zh) 2013-03-20
HK1183029A1 (zh) 2013-12-13
CN105367577B (zh) 2019-04-23

Similar Documents

Publication Publication Date Title
RU2604062C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
US6949560B2 (en) Imidazo-substituted compounds as p38 kinase inhibitors
TWI617560B (zh) PI3Kδ 抑制劑以及其應用和生產方法
US7456185B2 (en) Substituted quinazoline compounds useful as p38 kinase inhibitors
WO2008068171A9 (en) Substituted pyrimidines and their use as jnk modulators
WO2023186069A1 (zh) 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
RU2378275C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИНА И СПОСОБ ИХ ПОЛУЧЕНИЯ
CN116903613A (zh) 2-氧代喹唑啉并五元杂环衍生物、其制备方法及其应用
US5466706A (en) 9H-imidazo[1,2-A]benzimidazole-3-acetamide derivatives, their preparation and their therapeutic application
CA2799817A1 (en) Inhibitors of jnk
EP2576537B1 (en) 2-amino-pyrimidine derivatives useful as inhibitors of jnk
CN116836162A (zh) 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用
HK1183029B (en) Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
TW201217379A (en) Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
CN119431402A (zh) 噻唑并环类化合物及其应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200709